AlphaCentric Advisors’s Nektar Therapeutics NKTR Stock Holding History

AlphaCentric Advisors’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-300	Closed	-$77K	–	219
2020 Q4	$77K	Buy	+300	New	+$77.5K	0.03%	159

Other funds holding NKTR

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

AlphaCentric Advisors's NKTR Position: Q1 2021 in Review

AlphaCentric Advisors sold out of Nektar Therapeutics (NKTR) in Q1 2021, closing a stake of 300 shares — an estimated $77K sold.

AlphaCentric Advisors first reported a position in NKTR in Q4 2020 and held it in 1 quarter. The position peaked at $77K in Q4 2020. 235 funds tracked by Wall St. Rank hold NKTR as of Q1 2021.

AlphaCentric Advisors reported no remaining Nektar Therapeutics position as of Q1 2021 after selling out during the quarter.
AlphaCentric Advisors sold 300 Nektar Therapeutics shares in Q1 2021, an estimated $77K.
AlphaCentric Advisors first reported a position in Nektar Therapeutics in Q4 2020 and held it in 1 quarter.
AlphaCentric Advisors's Nektar Therapeutics position peaked at $77K in Q4 2020.
235 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2021.

Based on AlphaCentric Advisors's 13F filing for Q1 2021, filed 9 Mar 2022.